Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Valeant Pharmaceuticals for Mysimba® (naltrexone HCl / bupropion HCl prolonged release) for 18 Central and Eastern
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/10/2026
- Nasdaq ends sharply higher; chip surge offsets Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Key things to know ahead of SK Hynix’s blockbuster US listing
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- S&P Downgrades Oracle To 'bbb-/A-3'; Outlook Stable
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Citi names top picks in software ahead of Q2 earnings
RBC Capital Sees Tough Road Ahead Following Orexigen Therapeutics' (OREX) Takeda Partnership Termination; Cuts PT to $0.60
March 16, 2016 9:46 AM EDTRBC Capital maintained a Sector Perform rating on Orexigen Therapeutics (NASDAQ: OREX), and cut the price target to $0.60 (from $1.00), following the company's announced termination of the Takeda partnership. OREX plans to commercialize Contrave in the US by building its own commercial infrastructure. As... More
Leerink Lowers Leerink (OREX) PT to $1 on Move to Acquire Contrave Rights from Takeda
March 16, 2016 7:56 AM EDTLeerink Partners analyst, Paul Matteis, noted that Orexigen Therapeutics (NASDAQ: OREX) acquired the Contrave rights from Takeda and lowered his price target to $1 (from $2) on shares as a result. The firm maintained its Market Perform rating.
Yesterday morning OREX announced that it has entered into a deal with Takeda where it will acquire US commercial rights to Contrave; concurrently, OREX also... More
Piper Jaffray Downgrades Orexigen Therapeutics (OREX) to Neutral
March 16, 2016 6:35 AM EDTPiper Jaffray downgraded Orexigen Therapeutics (NASDAQ: OREX) from Overweight to Neutral with a price target of $2.00 (from $5.00).
Analyst Charles Duncan commented, "Yesterday Orexigen announced it plans to terminate its commercial partnership with Takeda for Contrave in the US market. We believe this... More
JMP Securities Downgrades Orexigen Therapeutics (OREX) to Market Perform
March 16, 2016 6:34 AM EDTJMP Securities downgraded Orexigen Therapeutics (NASDAQ: OREX) from Market Outperform to Market Perform and removed its price target (prior $2.00).
For an analyst ratings summary and ratings history on Orexigen Therapeutics click here. For more ratings news on Orexigen Therapeutics click here.
Shares of Orexigen Therapeutics closed at $0.64 yesterday.
... More